Ronchi Cristina L, Varca Virginia, Giavoli Claudia, Epaminonda Paolo, Beck-Peccoz Paolo, Spada Anna, Arosio Maura
Institute of Endocrine Sciences, Padiglione Granelli, Ospedale Maggiore Instituto di Ricovero e Cura a Carattere Scientifico, Via F. Sforza, 35, 20122 Milan, Italy.
J Clin Endocrinol Metab. 2005 Mar;90(3):1377-82. doi: 10.1210/jc.2004-1974. Epub 2004 Dec 7.
Criteria to define remission of acromegaly have changed over years. Since 2000, criteria for cure are normal IGF-I levels and a nadir GH after oral glucose tolerance test (OGTT) of less than 1 microg/liter, although recent studies have suggested to lower this cutoff value. This study reevaluated long-term disease activity of acromegalic patients, who were previously considered in remission, using these criteria. The study included 70 of 146 patients operated on between 1984 and 1996 who were considered cured based on normal IGF-I levels, GH values less than 2.5 microg/liter, and/or disappearance of abnormal GH response to TRH/GnRH. Among these 70 patients, 16 were lost to follow-up, three died, and 11 (one of whom had disease recurrence) only gave a phone interview. Forty patients participated in the study and were reevaluated for IGF-I levels and post-OGTT GH nadir after 14.3 +/- 4.2 (mean +/- sd) yr from surgery. In all patients, normal IGF-I levels and a post-OGTT GH nadir of less than 1 microg/liter were found. In particular, 19 patients had a GH nadir of less than 0.19 microg/liter, i.e. the upper limit (mean + 2 sd) found in 30 controls, whereas 21 patients had a nadir between 0.19 and 0.77 microg/liter. No significant differences in hormonal parameters and comorbidities between the two subgroups were observed. These data showed that lowering the post-OGTT GH cutoff value within the normal range does not seem to better discriminate patients with different disease activity or long-term recurrence risk.
多年来,肢端肥大症缓解的定义标准有所变化。自2000年以来,治愈标准为胰岛素样生长因子-I(IGF-I)水平正常且口服葡萄糖耐量试验(OGTT)后生长激素(GH)最低点低于1微克/升,不过最近的研究建议降低这一切断值。本研究使用这些标准重新评估了之前被认为已缓解的肢端肥大症患者的长期疾病活动情况。该研究纳入了1984年至1996年间接受手术的146例患者中的70例,这些患者基于IGF-I水平正常、GH值低于2.5微克/升和/或对促甲状腺激素释放激素(TRH)/促性腺激素释放激素(GnRH)的异常GH反应消失而被认为已治愈。在这70例患者中,16例失访,3例死亡,11例(其中1例疾病复发)仅接受了电话访谈。40例患者参与了研究,并在手术后14.3±4.2(均值±标准差)年重新评估了IGF-I水平和OGTT后GH最低点。在所有患者中,均发现IGF-I水平正常且OGTT后GH最低点低于1微克/升。特别是,19例患者的GH最低点低于0.19微克/升,即30例对照中发现的上限(均值+2标准差),而21例患者的最低点在0.19至0.77微克/升之间。两个亚组之间在激素参数和合并症方面未观察到显著差异。这些数据表明,在正常范围内降低OGTT后GH的截断值似乎并不能更好地区分具有不同疾病活动或长期复发风险的患者。